123 related articles for article (PubMed ID: 21467602)
1. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS).
Castro-Pastrana LI; Ghannadan R; Rieder MJ; Dahlke E; Hayden M; Carleton B
J Popul Ther Clin Pharmacol; 2011; 18():e106-20. PubMed ID: 21467602
[TBL] [Abstract][Full Text] [Related]
2. Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database.
Tanoshima R; Khan A; Biala AK; Trueman JN; Drögemöller BI; Wright GEB; Hasbullah JS; Groeneweg GSS; Ross CJD; Carleton BC;
J Clin Pharmacol; 2019 Mar; 59(3):356-363. PubMed ID: 30452777
[TBL] [Abstract][Full Text] [Related]
3. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse drug reactions to psychotropic drugs and their risk factors - a case-control study.
Greil W; Zhang X; Stassen H; Grohmann R; Bridler R; Hasler G; Toto S; Bleich S; Kasper S
Eur Neuropsychopharmacol; 2019 Jan; 29(1):111-121. PubMed ID: 30424913
[TBL] [Abstract][Full Text] [Related]
5. Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics.
Mushiroda T
J Hum Genet; 2023 Mar; 68(3):227-230. PubMed ID: 35534674
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Cutaneous Adverse Drug Reactions (ADR) Reported at an ADR Monitoring Center of a Tertiary Care Teaching Institute in Central India.
Chindhalore CA; Gupta AV; Dakhale GN; Srivastava A
Cureus; 2024 Feb; 16(2):e53706. PubMed ID: 38455795
[TBL] [Abstract][Full Text] [Related]
7. Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study.
Wang F; Zhao YK; Li M; Zhu Z; Zhang X
Cutan Ocul Toxicol; 2017 Dec; 36(4):370-376. PubMed ID: 28423957
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous cutaneous adverse drug reaction reports-An analysis of a 10-year dataset in Singapore.
Wong SX; Tham MY; Goh CL; Cheong HH; Chan SY
Pharmacol Res Perspect; 2019 Apr; 7(2):e00469. PubMed ID: 30911397
[TBL] [Abstract][Full Text] [Related]
9. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population.
Mushiroda T; Takahashi Y; Onuma T; Yamamoto Y; Kamei T; Hoshida T; Takeuchi K; Otsuka K; Okazaki M; Watanabe M; Kanemoto K; Oshima T; Watanabe A; Minami S; Saito K; Tanii H; Shimo Y; Hara M; Saitoh S; Kinoshita T; Kato M; Yamada N; Akamatsu N; Fukuchi T; Ishida S; Yasumoto S; Takahashi A; Ozeki T; Furuta T; Saito Y; Izumida N; Kano Y; Shiohara T; Kubo M;
JAMA Neurol; 2018 Jul; 75(7):842-849. PubMed ID: 29610831
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance of cutaneous adverse drug reactions in associations with drugs and medical conditions: a retrospective study of hospitalized patients.
Zheng L; Jin HB; Guan YY; Yang J
BMC Pharmacol Toxicol; 2022 Aug; 23(1):62. PubMed ID: 35948985
[TBL] [Abstract][Full Text] [Related]
11. Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC; Smith MA; Gelin MN; Heathcote SC
Can J Clin Pharmacol; 2007; 14(1):e45-57. PubMed ID: 17297195
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program.
Lange-Asschenfeldt C; Grohmann R; Lange-Asschenfeldt B; Engel RR; Rüther E; Cordes J
J Clin Psychiatry; 2009 Sep; 70(9):1258-65. PubMed ID: 19538904
[TBL] [Abstract][Full Text] [Related]
14. Incidence of cutaneous adverse drug reactions among medical inpatients of Sultanah Aminah Hospital Johor Bahru.
Latha S; Choon SE
Med J Malaysia; 2017 Jun; 72(3):151-156. PubMed ID: 28733562
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Adverse Drug Reactions (CADRs)-Statistical Analysis of the Causal Relationship between the Drug, Comorbidities, Cofactors, and the Cutaneous Reaction-A Single-Centered Study.
Machoń N; Lewandowska J; Zdanowska N; Placek W; Owczarczyk-Saczonek A
Int J Environ Res Public Health; 2022 Jun; 19(13):. PubMed ID: 35805639
[TBL] [Abstract][Full Text] [Related]
16. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance.
Turk BG; Gunaydin A; Ertam I; Ozturk G
Cutan Ocul Toxicol; 2013 Mar; 32(1):41-5. PubMed ID: 22812902
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine: Most Common Cause of Cutaneous Adverse Drug Reactions in an Outpatient Department of a Tertiary Care Hospital.
Pawar MP; Pore SM; Pradhan SN; Burute SR; Bhoi UY; Ramanand SJ
J Clin Diagn Res; 2015 Nov; 9(11):FC17-20. PubMed ID: 26672558
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Analysis of Pattern of Cutaneous Adverse Drug Reactions in Tertiary Hospital of Pauri Garhwal.
Dimri D; Raina RS; Thapliyal S; Thawani V
J Clin Diagn Res; 2016 May; 10(5):FC01-6. PubMed ID: 27437240
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse drug reactions notified by pharmacovigilance in a tertiary care hospital in north India.
Mittal N; Gupta M; Singla M
Cutan Ocul Toxicol; 2014 Dec; 33(4):289-93. PubMed ID: 24517496
[TBL] [Abstract][Full Text] [Related]
20. Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.
Tan-Koi WC; Sung C; Chong YY; Lateef A; Pang SM; Vasudevan A; Aw D; Lui NL; Lee SX; Ren EC; Koay ES; Tay YK; Lim YL; Lee HY; Dong D; Loke C; Tan L; Limenta M; Lee EJ; Toh D; Chan CL
Pharmacogenomics; 2017 Jun; 18(9):881-890. PubMed ID: 28594314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
